

Date: 5 April 2024

To.

The General Manager,
Department of Corporate Services,
BSE Limited
P.J. Towers, Dalal Street,
Mumbai – 400 001

Scrip Code: 543064

Dear Sir/ Ma'am,

Sub: Complaints Report in terms of Regulation 37 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read along with the master circular dated 20 June 2023 issued by the Securities and Exchange Board of India ("SEBI"), bearing reference no. SEBI/HO/CFD/POD-2/P/CIR/2023/93, as amended from time to time ("SEBI Master Circular").

Ref: Application for obtaining approval under Regulation 37 of the Listing Regulations for the scheme of amalgamation that seeks to amalgamate Cohance Lifesciences Limited ("Transferor Company") into and with Suven Pharmaceuticals Limited ("Transferee Company") under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013.

This is with reference to the captioned application submitted by us on 2 March 2024.

In terms of paragraph 6(a) of Part I(A) of the SEBI Master Circular, a listed entity is required to submit a "Report on Complaints" to the stock exchanges within 7 days of expiry of 21 days from the date of filing of the draft Scheme with the stock exchanges and hosting of the draft Scheme along with the documents specified under paragraph 2 of Part I(A) of the SEBI Master Circular on the websites of the stock exchanges and such listed entity. It may be noted that the exchange, i.e. BSE Limited ("BSE") hosted the draft Scheme of Amalgamation along with the required documents on its website (i.e., https://www.bseindia.com/corporates/NOCUnder.aspx) on 12 March 2024. The SEBI Master Circular requires the Reports on Complaints to be in the format prescribed in Annexure IV of the SEBI Master Circular.

In view of the above, we enclose the "Report on Complaints" as per the format prescribed under the SEBI Master Circular.

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai- 400093, Maharashtra, India Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad - 500081 Telangana, India Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236



As required under paragraph 6(b) of Part I(A) of the SEBI Master Circular, the Transferee Company will upload the "Report on Complaints" on its website, https://suvenpharm.com/

Thanking you,

Yours faithfully,

For Suven Pharmaceuticals Limited

Name: K. Hanumantha Rao

Designation: Company Secretary & Compliance Officer

E-mail ID: khrao@suvenpharm.com Telephone No.: +91-40-2354 9414

Encl.: As above.

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai- 400093, Maharashtra, India Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad - 500081 Telangana, India Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236



Report on Complaints

Part A

Sr. No.	Particulars	Number	
1	Number of complaints received directly	Nil	
2	Number of complaints forwarded by Stock Exchanges/SEBI	Nil	
3	Total Number of complaints/ comments received (1+2)	Nil	
4	Number of complaints resolved	Not Applicable	
5	Number of complaints pending	Nil	

Part B

Sr. No.	Name of Complainant	Date of Complaint	Status (Resolved/pending)		
Not Applicable					

For Suven Pharmaceuticals Limited

Name: K. Hanumantha Rao

Designation: Company Secretary & Compliance Officer

E-mail ID: khrao@suvenpharm.com Telephone No.: +91-40-2354 9414

Suven Pharmaceuticals Limited